RI・腫瘍病態学分野では、モデルマウスを用いた悪性腫瘍・難治性疾患の病態解明に関する研究を行っています。これまで、ヒトの細胞を超免疫不全マウスに移植することで、Patient-derived xenograft(PDX)モデルを含めたモデルマウスを作製し、液性因子や転写因子の制御に焦点を当てた悪性腫瘍の病態解明及び治療法の開発を行ってきました(Cancer Sci 2012, Cancer Lett 2013, Int J Hematol 2013, Eur J Cancer 2014, J Cancer Res Clin Oncol 2015, Leuk Res 2016, Oncogene 2017, Neoplasia 2024)。また、時間的・空間的に遺伝子を操作した遺伝子改変マウスを用いて、がん抑制に関わるシグナル伝達経路の機能解析を行ってきました(Oncogene 2017, Development 2018)。さらに、新たな白血病モデルマウスや患者検体を用いて、造血幹細胞レベルでの病態解析研究に参画して参りました(Cancer Cell 2021, Nat med 2022)。 今後も、悪性腫瘍・難治性疾患に対する新たな診断法・治療法の開発に取り組んで参ります(Explor Target Antitumor Ther 2024, Blood Rev 2025)。

​

In our lab, we conduct research aimed at elucidating the mechanisms underlying malignant tumors and intractable diseases using model mice. To date, we have developed model mice, including patient-derived xenograft (PDX) models, by transplanting human cells into highly immunodeficient mice. This approach has enabled us to investigate the pathophysiology of malignant tumors and develop therapeutic strategies, focusing on the regulation of humoral factors and transcription factors (Cancer Sci 2012, Cancer Lett 2013, Int J Hematol 2013, Eur J Cancer 2014, J Cancer Res Clin Oncol 2015, Leuk Res 2016, Oncogene 2017, Neoplasia 2024). Additionally, we have analyzed the functions of cancer-suppressing signaling pathways using genetically engineered mice with temporally and spatially controlled gene modifications (Oncogene 2017, Development 2018). Furthermore, we have participated in pathological analyses at the hematopoietic stem cell level, employing novel leukemia model mice and patient-derived samples (Cancer Cell 2021, Nat Med 2022). We will continue to work on developing new diagnostic and therapeutic approaches for malignant tumors and intractable diseases (Explor Target Antitumor Ther 2024, Blood Rev 2025).